SPAC company EureKING plans to acquire SCTbio, supporting the firm’s ambition to create a European bio-CDMO leader. EureKING, a “blank-check” company — also known as a special-purpose acquisition company, or SPAC — announced in May 2022 its aim to form a contract development manufacturing organization (CDMO) to be listed on Euronext Paris. The proposed acquisition of cell and gene therapy (CGT) CDMO SCTbio will see eureKING pay approximately €13.08 million ($14.35 million) for 67% of the share capital. The remaining…